Suraksha Diagnostic Ltd is Rated Hold

Current Rating Overview

On 11 August 2025, Suraksha Diagnostic Ltd’s rating was revised to 'Hold' from 'Sell', accompanied by a 10-point increase in its Mojo Score, moving from 42 to 52. This rating indicates a neutral stance, suggesting that the stock is fairly valued relative to its risk and return profile. Investors should interpret this as a signal to maintain existing positions rather than aggressively buying or selling the stock at this time.

Here’s How the Stock Looks Today

As of 22 January 2026, Suraksha Diagnostic Ltd remains a smallcap player in the Healthcare Services sector. The company’s current Mojo Grade of 'Hold' reflects a balanced assessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall recommendation and helps investors understand the stock’s potential risks and rewards.

Quality Assessment

The company’s quality grade is rated as 'good', underpinned by a strong ability to service its debt obligations. Suraksha Diagnostic Ltd maintains a low Debt to EBITDA ratio of 0.87 times, signalling prudent leverage management and financial stability. Additionally, the company has demonstrated healthy long-term growth, with operating profit expanding at an impressive annual rate of 89.29%. This robust profitability growth is a positive indicator of operational efficiency and market demand for its services.

However, some caution is warranted as recent half-year data shows a rise in interest expenses to ₹5.48 crores, growing at 35.64%, and a Debt-Equity ratio of 0.51 times, which is the highest recorded in the recent period. The operating profit to interest coverage ratio has dipped to 8.67 times, the lowest quarterly figure, suggesting that while debt servicing remains manageable, the margin of safety has narrowed somewhat.

Valuation Considerations

Suraksha Diagnostic Ltd’s valuation is graded as 'fair'. The company’s Return on Capital Employed (ROCE) stands at 15.8%, which is respectable within the healthcare services sector. Its Enterprise Value to Capital Employed ratio is 4.8, indicating that the stock is not excessively priced relative to the capital it employs to generate earnings. This valuation metric supports the 'Hold' rating, implying that the stock is trading near its intrinsic value and does not offer significant upside at current levels.

Despite this, investors should note that over the past year, the stock has delivered a negative return of approximately -18.85%, underperforming broader benchmarks such as the BSE500. This underperformance contrasts with a 34% rise in profits over the same period, highlighting a disconnect between market sentiment and company fundamentals.

Financial Trend Analysis

The financial trend for Suraksha Diagnostic Ltd is currently 'flat'. While the company has shown strong profit growth, recent results have been largely stable without significant acceleration. The flat trend is reflected in the company’s half-yearly results, which have not shown marked improvement, and in the stock’s price performance, which has been subdued over the last six months with a decline of 13.47% and a year-to-date gain of just 0.99%.

Institutional investors hold a significant 36.03% stake in the company, which is a positive sign. These investors typically have greater resources and expertise to analyse company fundamentals, lending credibility to the current valuation and outlook. However, the stock’s below-par performance over the last one and three years suggests that the market remains cautious about its near-term prospects.

Technical Outlook

The technical grade for Suraksha Diagnostic Ltd is described as 'sideways'. This indicates that the stock price has been trading within a range without clear directional momentum. The recent price movements show a lack of strong buying or selling pressure, which aligns with the 'Hold' rating. Investors should be aware that the sideways trend may persist until there is a catalyst to drive the stock decisively higher or lower.

Short-term returns have been mixed, with a 1-week gain of 1.82% offset by a 1-month decline of 1.97%. Over three months, the stock has fallen by 12.64%, reflecting some volatility and uncertainty in market sentiment.

What the 'Hold' Rating Means for Investors

The 'Hold' rating assigned to Suraksha Diagnostic Ltd suggests that the stock is currently fairly valued given its financial health, growth prospects, and market conditions. Investors holding the stock may consider maintaining their positions while monitoring developments closely. New investors might prefer to wait for clearer signs of upward momentum or improved financial trends before committing capital.

Given the company’s strong quality metrics but flat financial trends and sideways technicals, the stock does not presently offer compelling reasons for aggressive buying. Conversely, the manageable debt levels and fair valuation reduce the risk of significant downside, making it a relatively stable holding within the healthcare services sector.

Summary

In summary, Suraksha Diagnostic Ltd’s current 'Hold' rating by MarketsMOJO, updated on 11 August 2025, reflects a balanced view of the company’s strengths and challenges as of 22 January 2026. The stock exhibits good quality fundamentals, fair valuation, flat financial trends, and sideways technical patterns. While profit growth remains robust, recent price performance and market sentiment have been subdued, warranting a cautious but steady approach from investors.

Investors should continue to track key financial indicators such as operating profit growth, debt servicing ratios, and institutional activity, alongside broader market conditions, to reassess the stock’s outlook in the coming quarters.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →